Syncromune is a clinical-stage biopharmaceutical company focused on developing advanced immunotherapies for metastatic solid tumor cancers. The company is pioneering combination immunotherapies, which are considered the future of cancer treatment. Their flagship product, SYNC-T™, is a personalized in situ combination multi-target cancer therapy that combines partial oncolysis of a tumor with the infusion of a multi-target biologic drug directly into the tumor, aiming to enhance the immune system's ability to recognize and attack cancer.
Syncromune has made significant strides in the field of cancer immunotherapy, positioning itself as a leader in innovative cancer treatments. The company's approach has garnered attention from thought leaders in oncology, highlighting its potential impact on future cancer therapies. Syncromune's dedication to advancing personalized medicine is reflected in its cutting-edge research and development efforts, contributing to the broader goal of improving outcomes for patients with metastatic cancers.
